CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

CRISPR Ther­a­peu­tics is mak­ing sev­er­al changes to its al­lo­gene­ic CAR-T cell ther­a­py pipeline, in­clud­ing pro­gram cuts and mov­ing in­to a new in­di­ca­tion as it awaits an FDA de­ci­sion on its Ver­tex-part­nered CRISPR-edit­ed ther­a­py exa-cel.

The Swiss com­pa­ny is ax­ing two of its orig­i­nal CAR-T pro­grams — CTX110 and CTX130 — to pri­or­i­tize two next-gen­er­a­tion can­di­dates with the po­ten­tial for im­proved clin­i­cal pro­files ac­cord­ing to pre­lim­i­nary da­ta from ear­ly tri­als. CRISPR said it will tran­si­tion pa­tients treat­ed with CTX110 and CTX130 to long-term fol­low-up pro­grams where rel­e­vant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER